风湿免疫科指南

订阅

MedSci主页 / 所有栏目 / 风湿免疫科指南

2021 ISHLT共识文件：结缔组织病患者肺移植—第Ⅱ部分

2021-07-29 国际心肺移植协会 The Journal of Heart and Lung Transplantation

结缔组织病

2021年7月，国际心肺移植协会(ISHLT)发布了结缔组织病患者肺移植共识第Ⅱ部分，主要内容涉及心脏、外科、围手术期、手术技术以及术后管理的相关内容。

中文标题：

2021 ISHLT共识文件：结缔组织病患者肺移植—第Ⅱ部分

英文标题：

ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part II

发布机构：

国际心肺移植协会

发布日期：

2021-07-29

简要介绍：

2021年7月，国际心肺移植协会(ISHLT)发布了结缔组织病患者肺移植共识第Ⅱ部分，主要内容涉及心脏、外科、围手术期、手术技术以及术后管理的相关内容。结缔组织病（CTD）患者存在特殊的外科、围术期、手术以及术后挑战，本文主要针对上述内容提供指导建议。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 ISHLT共识文件：结缔组织病患者肺移植—第Ⅱ部分.pdf)] GetToolGuiderByIdResponse(projectId=1, id=94a411c0021995ec, title=2021 ISHLT共识文件：结缔组织病患者肺移植—第Ⅱ部分, enTitle=ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part II, guiderFrom=The Journal of Heart and Lung Transplantation, authorId=0, author=, summary=2021年7月，国际心肺移植协会(ISHLT)发布了结缔组织病患者肺移植共识第Ⅱ部分，主要内容涉及心脏、外科、围手术期、手术技术以及术后管理的相关内容。, cover=https://img.medsci.cn/2021101/1633096461138_5579292.jpg, journalId=0, articlesId=null, associationId=56, associationName=国际心肺移植协会, associationIntro=ISHLT成立于1981年，最初是一个只有15名心脏病学家和心脏外科医生的小团体，现在协会拥有超过2500名来自45个国家、14个与终末期心肺移植管理和治疗相关的不同学科领域的会员。多国家、多学科间的交流碰撞是协会发展的最大动力，为我们带来了更具广度和深度的教育资源，并提供了一个特别的非正式的信息沟通交流环境。, copyright=0, guiderPublishedTime=Thu Jul 29 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年7月，国际心肺移植协会(ISHLT)发布了结缔组织病患者肺移植共识第Ⅱ部分，主要内容涉及心脏、外科、围手术期、手术技术以及术后管理的相关内容。结缔组织病（CTD）患者存在特殊的外科、围术期、手术以及术后挑战，本文主要针对上述内容提供指导建议。</span></p>, tagList=[TagDto(tagId=11980, tagName=结缔组织病)], categoryList=[CategoryDto(categoryId=15, categoryName=风湿免疫科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=11980, guiderKeyword=结缔组织病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=10, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5045, appHits=89, showAppHits=0, pcHits=1564, showPcHits=4956, likes=0, shares=4, comments=3, approvalStatus=1, publishedTime=Fri Oct 01 22:00:33 CST 2021, publishedTimeString=2021-07-29, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Fri Oct 01 21:57:27 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 21:49:22 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 ISHLT共识文件：结缔组织病患者肺移植—第Ⅱ部分.pdf)])
2021 ISHLT共识文件：结缔组织病患者肺移植—第Ⅱ部分.pdf
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1057192, encodeId=dcdf105e192fd, content=不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Oct 03 17:25:50 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057054, encodeId=dcb9105e054a1, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Oct 03 08:05:39 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056893, encodeId=a4f710568936d, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Oct 02 07:23:14 CST 2021, time=2021-10-02, status=1, ipAttribution=)]
    2021-10-03 微探

    不错不错

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1057192, encodeId=dcdf105e192fd, content=不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Oct 03 17:25:50 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057054, encodeId=dcb9105e054a1, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Oct 03 08:05:39 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056893, encodeId=a4f710568936d, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Oct 02 07:23:14 CST 2021, time=2021-10-02, status=1, ipAttribution=)]
    2021-10-03 微探

    学习学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1057192, encodeId=dcdf105e192fd, content=不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Oct 03 17:25:50 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057054, encodeId=dcb9105e054a1, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Oct 03 08:05:39 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056893, encodeId=a4f710568936d, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Oct 02 07:23:14 CST 2021, time=2021-10-02, status=1, ipAttribution=)]
    2021-10-02 微探

    学习学习

    0

拓展阅读

2021 ISHLT共识文件：结缔组织病患者肺移植—第Ⅲ部分

国际心肺移植协会(ISHLT,The International Society of Heart and lung Transplantantion) · 2021-07-31

2022 麦哲伦临床医疗指南：基因检测-主动脉病和结缔组织疾病

麦哲伦医疗保健 Magellan Healthcare · 2022-07-01

2023年台湾心脏病学会(TSOC)和台湾风湿病学院(TCR)联合共识：结缔组织病相关性肺动脉高压

台湾心脏病学会(TSOC,Taiwan Society of Cardiology) · 2023-03-12